Skip to main content

Oelschlager Kristen M's Form 4/A amendment

Amended

Castle Biosciences Inc (CSTL) · filed Nov 4, 2025

Accession no.
0001628280-25-049176
Filed
Nov 4, 2025
Trade date
Aug 27, 2025
Filing delay
69 days
Rule 10b5-1 plan
Not checked
Original filed
Aug 29, 2025

This filing lists 1 non-derivative transaction. Open-market sales total $390.6K. It was filed 69 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Oelschlager Kristen MCIK 0001856565Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 27, 2025Common StockSSaleDisposed−18,007$21.69F1−$390,571.83100,937Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This transaction was executed in multiple trades at prices ranging from $21.24 to $21.94, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F2

On August 29, 2025, the Reporting Person filed a Form 4 which inadvertently reported that shares were sold by the Reporting Person directly. In fact, as reported in this amendment, the shares were sold by the Fritz Shorter Trust (the "Trust"). The original Form 4 also mistakenly indicated the wrong number of shares held by the Reporting Person directly and indirectly through the Trust. In fact, following this sale, the Reporting Person held 52,924 shares of common stock directly and 100,937 shares of common stock indirectly through the Trust. In addition, following a reconciliation of the reporting person's holdings, it was determined that the balance previously reported was understated by 68 shares, and the holdings reported herein have been adjusted accordingly.

F3

On March 19, 2025 and on August 22, 2025, the Reporting Person transferred 96,322 and 22,622 shares to the Trust. The transfer was not a change in beneficial ownership because the Reporting Person and her spouse are the trustees and sole beneficiaries of the Trust, the Trust is revocable and the Reporting Person has voting and investment power over the shares held by the Trust.

Read the full filing on SEC EDGAR (opens in a new tab)